Prodotti competitors / Area Kite 12 giugno 2023 Cell Therapy - CHMP Minutes for the Meeting on 27-30 March 2023
Prodotti competitors / Area Kite 8 maggio 2023 NICE advice and quality standards Interventional procedures guidance for Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma
Prodotti competitors / Area Kite 21 aprile 2023 Polatuzumab vedotin-piiq: FDA approval for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma
Prodotti competitors 9 marzo 2023 Oncologic Drugs Advisory Committee - Benefit-Risk Profile of Genentech’s Polivy to Treat Untreated DLBCL
Prodotti competitors / Area Onco-Ema 7 marzo 2023 polatuzumab vedotin (Polivy) in prima linea nel linfoma diffuso a grandi cellule B (DLBCL) : iter di P&R
Prodotti competitors / Area Kite 6 marzo 2023 NICE technology appraisal guidance: Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma
Prodotti competitors / Area Kite 9 febbraio 2023 US - FDA Oncologic Drugs Advisory Committee (ODAC) meeting on March 9, 2023 Genentech’s Polivy (polatuzumab vedotin-piiq)
